Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $406.8M | $566.1M | $637.3M | $684.6M | $655.4M | $545.7M | $478.8M | $340.6M |
| Cost of revenue | $100.5M | $256.0M | $332.1M | $395.9M | $411.8M | $380.5M | $403.2M | $307.4M |
| Gross profit | $306.4M | $310.1M | $305.2M | $288.7M | $243.6M | $165.2M | $75.6M | $33.2M |
| Gross margin | 75.3% | 54.8% | 47.9% | 42.2% | 37.2% | 30.3% | 15.8% | 9.7% |
| R&D | $30.3M | $45.1M | $42.1M | $29.2M | $38.8M | $30.0M | $24.2M | $22.4M |
| Operating income | $226.5M | $130.8M | $86.4M | $129.7M | $59.5M | −$1.4M | −$16.7M | −$70.2M |
| EBITDA | $233.1M | $161.5M | $145.3M | $191.8M | $115.8M | $53.6M | $19.4M | −$117.8M |
| Net income | $149.9M | $44.8M | −$581.0K | $28.7M | −$272.1M | −$33.4M | −$363.5M | −$231.6M |
| Net margin | 36.8% | 7.9% | -0.1% | 4.2% | -41.5% | -6.1% | -75.9% | -68.0% |
| EPS (diluted) | 1.01 | 0.30 | -0.00 | 0.19 | -1.76 | -0.21 | -2.29 | -22.96 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds LCI.
No tracked institution reports a position in LCI as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-02-07 | 1-for-4reverse |
| 2003-03-03 | 5-for-2 |
No one on the platform has traded LCI yet.
| $7M |
| — |
| MODVModivCare Inc. | $0.43 | +0.00% | $6M | — |
| NLTXNeoleukin Therapeutics, Inc. | $3.49 | +1.45% | $8M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.